Fig. 3
68Ga-Pentixafor-PET imaging of hematologic and solid cancer patients. Enhanced uptake of 68Ga-Pentixafor in bone marrow tissue in MM patient #26 and bone marrow lesions in MM patient #23 [79]. B Enhanced uptake of 68Ga-Pentixafor in bone marrow tissue in recurrent WM patient #5 and multiple lymph nodes of WM patient #11 [81]. C 68Ga-Pentixafor PET imaging and corresponding CE-T1w MRI imaging of recurrent CNSL patient #1 at time points of pre-treatment, completed chemotherapy (week 8), and completed radiotherapy (week 25) [85]. D 68Ga-Pentixafor PET/MRI imaging and HE staining of post-treatment MALT patients #2 and #9 [90]. E and F The average SUVmax and TBR of 68Ga-Pentixafor in solid cancer patients [87]. MM, multiple myeloma; WM, waldenström macroglobulinemia; CNSL, central nervous system lymphoma; NSCLC, non–small cell lung carcinoma; NEN, neuroendocrine neoplasm; AML, acute myeloid leukemia; CCC, cholangiocarcinoma; CLL, chronic lymphocytic leukemia; MZL, marginal zone lymphoma; DSRCT, desmoplastic small round cell tumor; SCLC, small cell lung carcinoma; ALL, acute lymphoblastoid leukemia. All panels were reproduced with permission